About this trial
Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig's Disease, is a progressive, terminal condition of muscle weakness that is associated with degeneration of neurons in the spinal cord and brain. This devastating disorder afflicts people in the prime of their lives. At the present time, there are no cures for this disorder, and current treatments are marginal at best. Despite years of intensive research, a fundamental understanding of this disease is still lacking. There is a need to identify both reliable markers of disease progression and effective treatments. The goal of this research is to bring a greater understanding of ALS patients closer to the research studies that can lead to new hypotheses and approaches.
Eligibility criteria
Qualifiers
Patients over the age of 18
Established diagnosis of ALS
Able and willing to give written informed consent and must authorize release and use of protected health information
Disqualifiers
Patients below the age of 18
No diagnosis of ALS
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
University of Illinois at Chicago
Lead sponsor
Tanabe Pharma America, Inc.
Collaborator